TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33613701
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor monotherapy
Study: 33613701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of baseline lesion number (BLN) and tumor mutation burden (TMB)
Study: 33614477
Drug: Antiviral prophylaxis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiviral prophylaxis
Study: 33614477
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral prophylaxis (Control)
Study: 33614504
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bortezomib, cyclophosphamide, and dexamethasone with daratumumab
Study: 33614504
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bortezomib, cyclophosphamide, and dexamethasone without daratumumab
Study: 33614888
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg daily for 24 weeks
Study: 33615207
Drug: NASH patients
Normalized name: nashipati extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASH patients with pronounced insulin resistance (IR)
Study: 33615399
Drug: Macimorelin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macimorelin 0.5 mg/kg
Study: 33615399
Drug: Macimorelin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macimorelin 0.75 mg/kg
Study: 33616416
Drug: Intraperitoneal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal bevacizumab 2.5 mg/kg
Study: 33616416
Drug: Intraperitoneal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal bevacizumab 5 mg/kg
Study: 33616416
Drug: Intraperitoneal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal bevacizumab 7.5 mg/kg
Study: 33616416
Drug: Intraperitoneal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal bevacizumab (all doses)
Study: 33616758
Drug: Pulse oximetry-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse oximetry-derived peripheral perfusion index (PPI) after 200 mL crystalloid challenge
Study: 33616758
Drug: Fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid challenge test using 200 mL crystalloid solution
Study: 33616758
Drug: Additional 300
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional 300 mL crystalloid infusion
Study: 33617672
Drug: DCLL9718S, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1)
Study: 33618437
Drug: Low-dose fludarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fludarabine and cyclophosphamide combined with rituximab (FCR); fludarabine reduced to 12 mg/m²
Study: 33618920
Drug: Hyperuricemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemic group (SUA ≥7 mg/dL in men and ≥6 mg/dL in women)
Study: 33619369
Drug: Daratumumab, carfilzomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone combination
Study: 33620177
Drug: Cyclic treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment interruption (CTI) of rosuvastatin for 72 weeks (3 treatment-interruption cycles)
Study: 33620904
Drug: Single purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single purified exosome product (PEP) injection (acute-single)
Study: 33620904
Drug: Weekly PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly PEP injections (acute-weekly, 4 total injections)
Study: 33620904
Drug: Delayed single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed single injection (subacute-single)
Study: 33620918
Drug: MemoryGel Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MemoryGel Breast Implants (primary augmentation)
Study: 33620918
Drug: MemoryGel Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MemoryGel Breast Implants (revision augmentation)
Study: 33620918
Drug: MemoryGel Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MemoryGel Breast Implants (primary reconstruction)
Study: 33620918
Drug: MemoryGel Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MemoryGel Breast Implants (revision reconstruction)
Study: 33621600
Drug: Inhaled amikacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin-containing multidrug regimens (including IV amikacin, imipenem or cefoxitin, oral azithromycin, and oral clofazimine if applicable)
Study: 33621600
Drug: Inhaled amikacin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin-containing multidrug regimens
Study: 33621914
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (DTCG), n = 22
Study: 33622371
Drug: High TIL
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation)
Study: 33622371
Drug: High TIL
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TIL treatments
Study: 33622371
Drug: High TIL
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TIL treatments after day 1
Study: 33622393
Drug: Preoperative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative use of pain medications
Study: 33622508
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment program (3 to 5 in-person sessions + weekly phone calls supported by a mobile app)
Study: 33622508
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment program
Study: 33624028
Drug: Elevated neutrophil
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated neutrophil count >7.8 × 10^9/L
Study: 33624233
Drug: LY3022855 (anti-CSF-1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022855 (anti-CSF-1R monoclonal antibody) 2.5 mg/kg QW, 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg Q2W, 1.25 mg/kg QW, 100 mg QW, 150 mg QW
Study: 33625039
Drug: Cell and
Normalized name: Antineoplastic cell and gene therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell and gene therapy for HIV disease, specific details on dosage and duration not available.
Study: 33625039
Drug: Vectored passive
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vectored passive immunity, B cell engineering, T cell engineering, specific details on dosage and duration not available.
Study: 33625060
Drug: Cafedrine hydrochloride
Normalized name: cafedrine
DrugBank: Cafedrine (DB12926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafedrine hydrochloride (200 mg) and theodrenaline hydrochloride (10 mg) in 2 ml (C/T)
Study: 33625371
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) administered intravenously at a loading dose of 30 mg/kg over 15 minutes, followed by a continuous infusion of 1 mg/kg/hour over the next 12 hours.
Study: 33625371
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) administered intravenously in an identical manner to VPA.
Study: 33625721
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day for 16 weeks
Study: 33625888
Drug: International camps
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: International camps for education and psychosocial support, details on dosage and duration not available.
Study: 33626238
Drug: Gefitinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib + Chemotherapy
Study: 33626251
Drug: Risdiplam (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam (0.08 mg/kg/day) in low-dose cohort
Study: 33626251
Drug: Risdiplam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam (0.2 mg/kg/day) in high-dose cohort
Study: 33626457
Drug: Fever-range whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fever-range whole body hyperthermia (FRWBH) scheduled weekly during re-irradiation; 5 patients received all cycles of FRWBH.
Study: 33626457
Drug: Re-irradiation using
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation using volumetric arc hyperfractionated radiotherapy with bi-daily 1.2 Gray (Gy) single fractions and a total dose of 66 Gy to all macroscopic tumor lesions; concomitant chemotherapy mostly with cisplatin (7 patients).
Study: 33627105
Drug: Antifibrotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic therapy
Study: 33627164
Drug: Moxetumomab pasudotox
Normalized name: Moxetumomab Pasudotox
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Moxetumomab pasudotox (40 µg/kg intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles)
Study: 33627169
Drug: Helmet CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helmet CPAP treatment
Study: 33627192
Drug: Amoxicillin treatment
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin treatment in a randomized controlled trial
Study: 33627313
Drug: D-dimers >1850
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimers >1850 ng/mL
Study: 33627355
Drug: Single high-sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-sensitivity cardiac troponin T (hs-cTnT) measurement <5 ng/L
Study: 33628355
Drug: Concurrent validity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent validity (preprocedure measurements)
Study: 33628355
Drug: Concurrent validity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent validity (postprocedure measurements)
Study: 33628834
Drug: Hybrid Closed
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid Closed Loop (HCL) insulin delivery system with integrated continuous glucose monitoring (CGM)
Study: 33629188
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) with warming and cooling sensations (hot tropical ginger, hot mango, cool red fruits, cool lemon, neutral)
Study: 33629819
Drug: Ticagrelor (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months)
Study: 33630272
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Tocilizumab (TCZ) therapy
Study: 33630272
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) therapy with known reasons for discontinuation
Study: 33630275
Drug: Daratumumab 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab 16 mg/kg monotherapy
Study: 33630808
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (100-mL intravenous lipid emulsion)
Study: 33631349
Drug: Accelerated neuromodulation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated neuromodulation therapy
Study: 33631774
Drug: Once-weekly prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly prophylaxis with nonacog alfa 100 IU/kg (12 months)
Study: 33631774
Drug: On-demand nonacog
Normalized name: nonacog alfa
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: On-demand nonacog alfa (6 months; dose at investigator's discretion)
Study: 33631774
Drug: Once-weekly prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly prophylaxis with nonacog alfa
Study: 33632155
Drug: CAR-T cell
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T cell infusion
Study: 33632171
Drug: Male participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male participants with SARS-CoV-2 antibodies
Study: 33632171
Drug: Female participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female participants with SARS-CoV-2 antibodies
Study: 33632262
Drug: BCI-FES hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCI-FES hand therapy system
Study: 33632707
Drug: Hyperinsulinemia measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemia measures (insulin, HOMA-IR, HOMA-%β)
Study: 33632755
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health solutions
Study: 33632874
Drug: NLG207 (Formerly
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLG207 (Formerly CRLX101) in combination with Enzalutamide
Study: 33633114
Drug: Lentivirus-mediated gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lentivirus-mediated gene therapy
Study: 33633977
Drug: One-stage direct-to-implant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage direct-to-implant technique using acellular dermal matrix (ADM)
Study: 33633977
Drug: Two-stage expander-to-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage expander-to-implant technique
Study: 33634616
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 2 (no gel)
Study: 33634616
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 1 (excipient-based gel)
Study: 33635141
Drug: Ibudilast 100
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast 100 mg/day
Study: 33636454
Drug: Inhaled Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled Azacitidine (15, 30, and 45 mg/m daily on days 1-5 and 15-19 of 28-day cycles)
Study: 33636454
Drug: Inhaled Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled Azacitidine (higher doses)
Study: 33636454
Drug: Inhaled Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled Azacitidine (pre- and post-treatment bronchoscopy)
Study: 38839252
Drug: Metformin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin use
Study: 33637087
Drug: Metformin initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin initiation
Study: 33638035
Drug: PIM447 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIM447 250 mg QD
Study: 33638035
Drug: PIM447 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIM447 300 mg QD
Study: 33638113
Drug: AKCEA-TTR-L
Normalized name: AKCEA-TTR-LRx
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-TTR-L
Study: 33638263
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (escitalopram or duloxetine) for 8 weeks
Study: 33638863
Drug: abaloparatide-sMTS 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: abaloparatide-sMTS 300 μg once daily for 29 days
Study: 33639190
Drug: DVH (best
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVH (best cut-off: V46Gy ≥80 cc)
Study: 33639190
Drug: Constrained bowel
Normalized name: Constrained Metal (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constrained bowel loops (V46 < 80 cc)
Study: 33639518
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation training with music therapy (2 sessions per week for 3 months)
Study: 33639900
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stem cells (UC-MSCs) injected intravenously at a dose of 1 × 10^6 cells/kg
Study: 33639900
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (IST)
Study: 33639987
Drug: Midkine inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midkine inhibition via adeno-associated virus (AAV) targeting; specific dosage and duration not mentioned.
Study: 33639987
Drug: Midkine levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midkine levels in plasma and lung; specific dosage and duration not mentioned.
Study: 33639987
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro study using inhibitors targeting candidate receptors of midkine; specific dosage and duration not mentioned.
Study: 33639990
Drug: Miransertib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miransertib treatment for a median duration of 22 months (range 22-28).
Study: 33640028
Drug: Facilitators identified
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facilitators identified include 'recognizing and addressing' by close others, 'waiting times and availability', 'recommendations and referrals' by health care professionals, and 'positive role models for treatment'.
Study: 33640346
Drug: His-optimized cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: His-optimized cardiac resynchronization therapy (HOT-CRT)
Study: 33640521
Drug: Patient-centered opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered opioid prescription guidelines
Study: 33640521
Drug: Nonopioid analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid analgesics
Study: 33640521
Drug: Prescribed pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed pills
Study: 33640578
Drug: Pre-treatment FDG-PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment FDG-PET and DWI-MR imaging parameters
Study: 33640871
Drug: Ribociclib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 300 mg three weeks in a row with a 1 week break and everolimus 2.5 mg daily (first 12 patients)
Study: 33640871
Drug: Ribociclib 200
Normalized name: ribociclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 200 mg and everolimus 2.5 mg daily (additional 9 patients)
Study: 33640871
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ribociclib and everolimus
Study: 33641211
Drug: Ixazomib (MLN9708)
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib (MLN9708) 4 mg in combination with Fulvestrant
Study: 33641374
Drug: 3-Month Dual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-Month Dual Antiplatelet Therapy
Study: 33641385
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) performed in 49 patients (32.7%; mechanical thrombectomy, n=43)
Study: 33643689
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) 6 or 8 Gy x 2 or 3 doses followed by 4 cycles of ipilimumab
Study: 33643905
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (AI) monotherapy
Study: 33644235
Drug: Neutralizing antibody
Normalized name: Neutralizing antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibody quantification using ELISA and luminescent SARS-CoV-2 pseudotype
Study: 33646302
Drug: HLA-haploidentical HSCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-haploidentical HSCT with age-adapted myeloablative conditioning and T-cell immunotherapy
Study: 33647009
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) at ≥20mg/L
Study: 33647009
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) at 0.5 ng/ml
Study: 33647286
Drug: EUS-guided verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EUS-guided verteporfin photodynamic therapy (PDT) at a dosage of 0.4 mg/kg infused 60 to 90 minutes before EUS, with light delivered at 50 J/cm for 333 seconds
Study: 33647286
Drug: EUS-guided verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EUS-guided verteporfin photodynamic therapy (PDT)
Study: 33647548
Drug: Sequential irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential irinotecan (Arm A)
Study: 33647913
Drug: Renal Autologous
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal Autologous Cell Therapy (REACT); 2 doses at 6-month intervals
Study: 33648577
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine gluconate solution
Study: 33649057
Drug: Psychoeducational intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational intervention: 3 weekly face-to-face consultations between dyads and trained nurses.
Study: 33650179
Drug: Weekly carfilzomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly carfilzomib (20/70 mg/m²), cyclophosphamide, and dexamethasone (wKCd)
Study: 33650972
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy